|
|
|
|
|
|
|
|
|
|
ScienceDirect.com - Gynecologic Oncology - Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer
Highlights
►
Complete or partial ORR was 75% with combination therapy.
► Response rate among subjects with first progression-free interval < 12 months (75%) was comparable to subjects with progression-free interval ≥ 12 (84%).
► In 21% of evaluable subjects, second progression-free interval was longer than first progression-free interval.
► Response rate among subjects with first progression-free interval < 12 months (75%) was comparable to subjects with progression-free interval ≥ 12 (84%).
► In 21% of evaluable subjects, second progression-free interval was longer than first progression-free interval.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.